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Abstract
Atypical antipsychotic drugs (APDs) increase dopamine (DA) release in prefrontal cortex (PFC), an eﬀect
probably mediated by the direct or indirect activation of the 5-HT1A receptor (5-HT1AR). Given the very
low in-vitro aﬃnity of most APDs for 5-HT1ARs and the large co-expression of 5-HT1ARs and 5-HT2A
receptors (5-HT2ARs) in the PFC, this eﬀect might result from the imbalance of 5-HT1AR and 5-HT2AR
activation after blockade of these receptors by APDs, for which they show high aﬃnity. Here we tested
this hypothesis by examining the dependence of the APD-induced DA release in medial PFC (mPFC) on
each receptor by using in-vivomicrodialysis in wild-type (WT) and 5-HT1AR and 5-HT2AR knockout (KO)
mice. Local APDs (clozapine, olanzapine, risperidone) administered by reverse dialysis induced a dose-
dependent increase in mPFC DA output equally in WT and 5-HT2AR KO mice whereas the DA increase
was absent in 5-HT1AR KO mice. To examine the relative contribution of both receptors to the clozapine-
induced DA release in rat mPFC, we silenced G-protein-coupled receptors (GPCRs) in vivo with
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) while 5-HT1ARs or 5-HT2A/2CRs in the mPFC
were selectively protected with the respective antagonists WAY-100635 or ritanserin. The inactivation of
GPCRs while preserving y70% of 5-HT2A/2CRs prevented the clozapine-induced DA rise in mPFC. In
contrast, clozapine increased DA in mPFC of EEDQ-treated rats whose 5-HT1ARs were protected (y50%
of control rats). These results indicate that (1) 5-HT1ARs are necessary for the APDs-induced elevation in
cortical DA transmission, and (2) this eﬀect does not require 5-HT2AR blockade by APDs.
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Introduction
Cognitive impairment, including attention disorders,
deﬁcits in working memory and executive functions,
is a central feature of schizophrenia lacking adequate
treatment (Braﬀ, 1993; Elvevag & Goldberg, 2000 ;
Green et al. 2000). Negative symptoms are also poorly
treated with current medications (Weickert et al.
2000), which, by themselves, induce this type of
symptomatology (Artaloytia et al. 2006). In particular,
atypical antipsychotic drugs (APDs) improve negative
symptoms and quality of life more than classical
antipsychotics (Sumiyoshi et al. 2006; Woodward et al.
2005). Moreover, some APDs (amisulpride, clozapine,
olanzapine, risperidone) proved superior to ﬁrst-
generation drugs when considering their overall eﬃ-
cacy (Leucht et al. 2009).
The ability of some APDs to improve negative/
cognitive symptoms (Bubenikova-Valesova et al. 2008;
Grayson et al. 2007; Harvey et al. 2008) has been at-
tributed to their capacity to increase dopamine (DA)-
mediated transmission in the medial prefrontal cortex
(mPFC) and hippocampus of experimental animals
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(Assie´ et al. 2005; Bortolozzi et al. 2007b ; Chung et al.
2004; Dı´az-Mataix et al. 2005; Elsworth et al. 2008;
Ichikawa et al. 2001; Kuroki et al. 1999; Li et al. 2009;
Millan, 2000 ; Rollema et al. 1997, 2000 ; Youngren
et al. 1999). Indeed, an optimal DA transmission is
fundamental for the execution of PFC-dependent
cognitive tasks (Vijayraghavan et al. 2007; Williams &
Goldman-Rakic, 1995) and, among other anatomical
and neurochemical abnormalities in PFC, schizo-
phrenia patients show a reduced dopaminergic
innervation (Akil et al. 1999; Lewis & Lieberman,
2000).
APDs share a higher in-vitro aﬃnity and in-vivo
occupancy of 5-HT2A receptors (5-HT2ARs) vs. DA D2
receptors (Meltzer et al. 1989; Nyberg et al. 1998;
Stockmeier et al. 1993). 5-HT2ARs are densely ex-
pressed in PFC, mainly in projection pyramidal
neurons (Amargo´s-Bosch et al. 2004; Lo´pez-Gime´nez
et al. 1997; Pazos et al. 1985; Santana et al. 2004),
including those projecting to the ventral tegmental
area (VTA) (Va´zquez-Borsetti et al. 2009). 5-HT2AR
stimulation in PFC enhances the activity of pyramidal
neurons projecting to the VTA (Puig et al. 2003, 2005)
and of VTA dopaminergic neurons (Bortolozzi et al.
2005), leading to an increased mesocortical DA release
(Bortolozzi et al. 2005; Gobert & Millan, 1999). Further,
the 5-HT2AR antagonist M100907 reduced the ﬁring of
DA neurons and DA release in mPFC (Bortolozzi et al.
2005; Minabe et al. 2001; Pehek et al. 2001). Overall,
these observations are consistent with the above
anatomical ﬁnding showing the existence of (a) closed
mPFC-VTA loops (Carr & Sesack, 2000) and (b) the
expression of 5-HT2ARs in mPFC pyramidal neurons
projecting to the VTA (Va´zquez-Borsetti et al. 2009).
However, 5-HT2AR blockade has been suggested to be
necessary for APDs to enhance DA release in the
mPFC (Bonaccorso et al. 2002; Ichikawa et al. 2001;
Lie´geois et al. 2002).
In addition to 5-HT2AR blockade, APDs display
variable, but often high aﬃnity for other monoamine
receptors (see http://kidb.case.edu/pdsp.php; Roth
et al. 2003). Agonist activity at 5-HT1A receptors
(5-HT1ARs) by APDs appears to contribute to their
superior eﬃcacy in treating non-psychotic symptoms
(Bantick et al. 2001; Meltzer & Sumiyoshi, 2008;
Millan, 2000 ; Sumiyoshi et al. 2001a, b ; but see Re¨nyi
et al. 2001; Yasuno et al. 2003). Hence, although APDs
show little or no in-vitro aﬃnity for 5-HT1ARs (Ki=
770 nM for clozapine, >1000 nM for olanzapine and
490 nM for risperidone; Arnt & Skarsfeldt, 1998;
Bymaster et al. 1996), these agents increase cortical DA
release through 5-HT1AR activation (Dı´az-Mataix et al.
2005; Rollema et al. 1997).
Given the large co-expression of 5-HT1A and 5-HT2A
receptors in PFC (Amargo´s-Bosch et al. 2004) and their
opposite role in modulating pyramidal neuron activity
(Aghajanian & Marek, 1997 ; Amargo´s-Bosch et al.
2004; Araneda & Andrade, 1991 ; Ashby et al. 1994;
Puig et al. 2005), the apparent in-vivo action of APDs
at 5-HT1ARs might be due to blockade of 5-HT2ARs
in cells co-expressing both receptors, thus enhancing
5-HT1AR-mediated neurotransmission. Here we ex-
amined this possibility using control mice and mice
lacking 5-HT1A or 5-HT2A receptors. We also used
an in-vivo rat model consisting in the inactivation of G-
protein-coupled receptors (GPCRs) with the alkylating
agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquino-
line (EEDQ), while selectively protecting 5-HT1A or
5-HT2A/2C receptors in themPFC (Amargo´s-Bosch et al.
2004).
Materials and methods
Animals
Male albino Wistar rats (250–320 g) were from Iﬀa
Credo (France). Male homozygous 5-HT1AR knockout
(KO) mice were generated at Princeton University)
(Parks et al. 1998) and 5-HT2AR KO mice were gener-
ated at Columbia University) (Fiorica-Howells et al.
2002). Both genotypes were gradually backcrossed to
the C57BL/6 background. From these initial sources,
some 5-HT1AR KO and 5-HT2AR KO mice were
transferred to develop a stable colony in our animal
facilities. Wild-type (WT) mice of the same genetic
background (C57BL/6) were also used. Mice were
aged 10–15 wk at the time of experiments. Animals
were maintained in a temperature-controlled room
with a 12-h light/dark cycle (lights on 08:00 hours).
Food and water were available ad libitum. Animal care
followed the European Union regulations (O.J. of E.C.
L358/1 18/12/1986) and was approved by the
Institutional Animal Care and Use Committee of the
School of Medicine, University of Barcelona.
Drugs and reagents
All reagents used were of analytical grade and
were obtained from Merck (Germany). 5-HT oxalate,
clozapine, 1-[2,5-dimethoxy-4-iodophenyl-2-amino-
propane] (DOI), dopamine hydrochloride, EEDQ,
risperidone, ritanserin, 6-chloro-5-methyl-1-[6-(2-
methylpyridin-3-yloxy) pyridin-3-yl carbamoyl]
indoline (SB-242084), spiperone and N-[2-(4-(2-meth-
oxyphenyl)-1-piperazinyl)ethyl]-N-(2-pyridyl) cyclo-
hexane carboxamide 3 HCl (WAY-100635) were
from Sigma/RBI (Spain). BAY x 3792, citalopram HBr
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and olanzapine were from Bayer, Lundbeck A/S
(Denmark) and Eli Lilly (USA), respectively. To assess
local eﬀects in microdialysis experiments, drugs were
dissolved in perfusion ﬂuid [aCSF (artiﬁcial cerebro-
spinal ﬂuid, mM) : NaCl, 125; KCl, 2.5 ; CaCl2, 1.26 and
MgCl2, 1.18] and administered by reverse dialysis at
the stated concentrations (uncorrected for membrane
recovery). Clozapine, olanzapine and risperidone
were initially dissolved in a drop of acetic acid and
diluted to appropriate concentrations in aCSF. All
other drugs were dissolved in distilled water, saline or
aCSF, as required. Concentrated solutions (1 mM; pH
adjusted to 6.5–7 with NaHCO3 when necessary) were
stored at x80 xC and working solutions were pre-
pared daily by dilution in aCSF. Control mice and rats
were perfused with aCSF. Bars in the ﬁgures show the
period of drug administration, corrected for the void
volume of the system.
Microdialysis procedures
Microdialysis experiments in rats and mice were con-
ducted as described previously (Amargo´s-Bosch et al.
2004; Bortolozzi et al. 2003). Rats were anaesthetized
with sodium pentobarbital (60 mg/kg i.p.) and im-
planted with 4-mm concentric dialysis probes
(Cuprophan) in the mPFC [coordinates in mm: AP
+3.2, L x0.8, DV x6.0 (Paxinos & Watson, 2005)].
Experiments were performed in awake animalsy20 h
after surgery. Probes were perfused with aCSF at
1.5 ml/min. After an initial 100 min stabilization per-
iod, four baseline samples were collected (20 min
each) before local drug administration, and successive
dialysate samples were collected. For mice, the surgi-
cal and microdialysis procedures were identical to
those described for rats, except for the dose of anaes-
thesia (40 mg/kg i.p.), length of dialysis membrane
(2 mm), and the brain coordinates (in mm) of the
mPFC: AP +2.2, L x0.2, DV x3.4 (Franklin &
Paxinos, 1997).
Monoamine concentration in dialysate samples was
determined by HPLC with electrochemical detection
(Hewlett Packard 1049; +0.75 for DA, +0.6 V for
5-HT) as described previously (Bortolozzi et al. 2003;
Dı´az-Mataix et al. 2005). Detection limits were 2–3 fmol
for DA and 5-HT.
At the end of the experiments, animals were
killed by an overdose of anaesthetic. Brains were
quickly removed and frozen in dry ice before being
sectioned (40 mm) with a cryostat (HM500-Om
Microm, Germany) in coronal planes. Brain sections
were stained with Neutral Red to verify the correct
placement of probes.
Silencing of GPCRs in vivo with selective protection
of 5-HT1ARs or 5-HT2A/2CRs in mPFC
We used a previously described strategy to selectively
protect 5-HT1ARs or 5-HT2A/2CRs in mPFC from
the overall inactivating eﬀect of EEDQ on GPCRs
(Amargo´s-Bosch et al. 2004). EEDQ was systemically
administered to inactivate GPCRs while selectively
protecting one or other receptor by the local perfusion
of selective antagonists (WAY-100635 for 5-HT1ARs,
ritanserin for 5-HT2A/2CRs) through the microdialysis
probes. EEDQ alkylates several GPCRs and inactivates
their function (Gozlan et al. 1994), except those whose
binding pockets are occupied. Thus, the perfusion of
WAY-100635 or ritanserin in mPFC confers a selective
protection of 5-HT1ARs or 5-HT2A/2CRs in mPFC,
respectively, during EEDQ treatment. These two
experimental groups are designated as GPCR-
silenced+5-HT1AR-protected and GPCR-silenced+
5-HT2A/2CR-protected, respectively.
Three to four hours after implantation, micro-
dialysis probes were perfused with WAY-100635
(300 mM) for 3 h at 1.5 ml/min (5-HT1AR protection).
One hour after starting the perfusion, EEDQ (dis-
solved in ethanol/water 1 :1) was administered at
6 mg/kg i.p. The same procedure was applied to pro-
tect 5-HT2A/2CRs using the 5-HT2A/2CR antagonist
ritanserin (300 mM). Control rats received vehicle in-
traperitoneally and aCSF through the dialysis probes.
On the following day, histological or microdialysis
experiments were performed. For autoradiographic
studies, 14-mm-thick coronal sections were cut, thaw-
mounted onto 3-aminopropyltriethoxysilane (APTS;
Sigma/RBI, Spain) coated slides, and kept at x20 xC
until required. All experiments with control and
EEDQ-treated rats were run in parallel.
Receptor autoradiography
To determine the extent of regional 5-HT1AR or
5-HT2A/2CR protection in EEDQ-treated rats we
performed receptor autoradiography for 5-HT1A and
5-HT2A/2C receptors using the ligands [
3H]8-OH-
DPAT (227.0 Ci/mmol) and [3H]mesulergine (83.0 Ci/
mmol), respectively, from Amersham (GE Healthcare,
Spain). Fresh frozen coronal sections of PFC from
control and EEDQ-treated rats were used. Incubation
conditions for [3H]8-OH-DPAT were as previously
described (Mengod et al. 1996). Non-speciﬁc binding
was deﬁned as that remaining in presence of 10x5 M
5-HT. Incubation conditions for [3H]mesulergine
were as previously described (Lo´pez-Gime´nez et al.
2002; Pazos et al. 1985). Non-speciﬁc binding was
deﬁned as that remaining in the presence of 10x5 M
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mianserin. After incubation and washing, tissue sec-
tions were dipped in distilled, ice-cold water and
dried rapidly under a cold air stream. Tissues were
exposed to tritium-sensitive ﬁlm (Kodak Biomax MR;
Kodak, USA) together with plastic 3H standards for
60 d at 4 xC. All tissue sections used for quantiﬁcation
of receptor sites were processed simultaneously under
the same conditions.
5-HT1A, 5-HT2A and 5-HT2C receptors were exam-
ined in mice brain by receptor autoradiography
as previously described (Lo´pez-Gime´nez et al. 2002;
Mengod et al. 1996; Pazos et al. 1985) using (a) [3H]8-
OH-DPAT for 5-HT1ARs, (b) [
3H]mesulergine (plus
10x7 M of the selective 5-HT2CR antagonist SB242084)
for 5-HT2ARs, and (c) [
3H]mesulergine (plus 10x7 M of
the 5-HT2AR antagonist spiperone) for 5-HT2CRs.
Quantitative analysis of the autoradiograms was
done with AIS computerized image analysis system
(Imaging Research Inc., Canada).
Data and statistical analysis
Microdialysis results are expressed as fmol/30-ml
fraction for DA and 5-HT and shown in the Figures as
percentages of baseline (individual means of four pre-
drug fractions). Area under the curve (AUC) of selec-
ted time periods (fractions 6–16) was also calculated.
Statistical analysis was performed using one- or two-
way ANOVAs for repeated measures or AUC of DA
or 5-HT values followed by Newman–Keuls post-hoc
test.
Quantitative autoradiographic measurements ob-
tained from the diﬀerent radioligands were analysed
using one-way ANOVA followed by Newman–Keuls
post-hoc test or Student’s t test, as appropriate. Data are
expressed as means¡S.E.M. Statistical signiﬁcance has
been set at the 95% conﬁdence level (two tailed).
Results
Basal values of DA and 5-HT in mPFC dialysates
Basal extracellular levels of DA and 5-HT in dialysates
from mPFC of mice and rats are shown in Table 1.
Non-signiﬁcant diﬀerences were found between mice
genotype or between control and EEDQ-pretreated
rats.
5-HT1AR and 5-HT2AR KO mice : receptor
autoradiography and neurochemical analysis
The lack of 5-HT1ARs in these KOmice was previously
assessed by autoradiography, electrophysiology
and microdialysis procedures (Amargo´s-Bosch et al.
2004). Here, we extended previous autoradiographic
observations. [3H]8-OH-DPAT binding to 5-HT1ARs
showed a high density in PFC, hippocampus and
raphe nuclei of WT mice (Fig. 1, panels A1–A3).
Homozygous 5-HT1AR KO mice showed no speciﬁc
binding in either region (Fig. 1, panels A4–A6).
The absence of 5-HT2ARs in these KO mice was
evaluated by receptor autoradiography and by the
neurochemical response to the preferential 5-HT2AR
agonist DOI. Autoradiographic analysis of 5-HT2ARs
revealed the presence of a strong signal in the frontal
cortex and claustrum of WT mice (Fig. 2, panels
A1-A2). Homozygous 5-HT2AR KO mice showed no
speciﬁc binding in either region (Fig. 2, panels A3–A4).
Quantitative assessments of 5-HT1AR and 5-HT2CR
density are shown in Table 2. No genotype diﬀerences
between the densities of 5-HT2CRs and 5-HT1ARs were
found in receptor-rich areas such as the choroid plexus
and PFC, respectively (Fig. 2b, c).
Perfusion of aCSF did not signiﬁcantly alter DA and
5-HT output in the mPFC of WT and 5-HT2AR KO
mice (DA, n=6 and 5, respectively ; 5-HT, n=5 for each
genotype) (Fig. 3a, b). Local administration of DOI
(100 mM for 5-HT and 300 mM for DA; see Bortolozzi
et al. 2003, 2005) enhanced 5-HT and DA output in the
mPFC of WT mice (Fig. 3c, d). DOI induced a maximal
elevation of the 5-HT output to 205¡19% of baseline
(n=10) [F(15, 135)=7.71, p<0.001]. Similarly, DOI
elevated DA output to 192¡23% of baseline (n=10)
[F(15, 135)=6.46, p<0.001]. Neither of these eﬀects
was observed when DOI was perfused in the mPFC of
5-HT2AR KO mice (Fig. 3c, d).
Eﬀect of atypical antipsychotics on mPFC DA output
in 5-HT1AR and 5-HT2AR KO mice
These experiments were conducted to examine
whether the increase in DA output induced by APDs
Table 1. Basal DA and 5-HT dialysate values in the mPFC
of mice and rats
Group
Baseline DA
(fmol/20-min
fraction)
Baseline 5-HT
(fmol/20-min
fraction)
WT mice 6.3¡0.8 (n=54) 17.2¡1.9 (n=25)
5-HT1AR KO mice 6.6¡0.8 (n=30) 19.7¡1.9 (n=9)
5-HT2AR KO mice 5.7¡0.6 (n=49) 16.5¡1.4 (n=24)
Control rats 8.9¡1.0 (n=27) n.e.
EEDQ pretreated rats 11.2¡1.6 (n=17) n.e.
n.e., Not examined.
Data are means¡S.E.M. of the number of animals shown in
parentheses.
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in mPFC is primarily associated with activation of 5-
HT1ARs or with blockade of 5-HT2ARs. Local admin-
istration of clozapine (300 mM), olanzapine (100 mM)
(Dı´az-Mataix et al. 2005) and risperidone (100 mM)
by reverse dialysis increased the DA concentration
similarly in the mPFC of WT and 5-HT2AR KO mice.
Two-way ANOVAs revealed a signiﬁcant eﬀect of
time and non-signiﬁcant eﬀects of genotype and
timergenotype interaction (Fig. 4a–c). The maximal
eﬀect induced by clozapine on mPFC DA output
was 428¡52% of baseline in WT mice (n=9) and
442¡54% of baseline in 5-HT2AR KOmice (n=9) [time
eﬀect : F(15, 240)=37.22, p<0.0001]. Olanzapine per-
fusion increased DA output to 363¡61% of basal
values in mPFC of WTmice (n=6) and to 348¡75% in
5-HT2AR KO mice (n=7) [time eﬀect : F(15, 165)=
10.84, p<0.0001], and the maximal elevation of mPFC
DA release produced by risperidone was 283¡71% of
A1 A2 A3
A4 A5 A6
DREnt
CA1
CA3
Cg1
PrL
IL
Fig. 1. Representative autoradiograms of [3H]8-OH-DPAT binding in the brains of wild-type (WT) (A1–A3, upper panels) and
5-HT1AR knockout (KO) mice (A4–A6, lower panels). In WT mice, note the high density for 5-HT1ARs in (A1) prefrontal cortex
[cingulated (Cg1), prelimbic (PrL), infralimbic (IL) ; AP: 1.78 mm), (A2) hippocampus (AP:x2.06 mm) and (A3) dorsal raphe
nuclei (DR) and entorhinal cortex (Ent) (AP:x4.36 mm). Parallel sections of the corresponding null mutant mice (KO) show a
lack of [3H]8-OH-DPAT binding (A4–A6). Scale bar, 1 mm.
(a) (b) (c)
A1 A2 B1 C1
A3 A4 B2 C2
Cg1
M2M1
Cg1
M2M1FCx
CL
ChP
Fig. 2. Representative autoradiograms of [3H]mesulergine (a, b) and [3H]8-OH-DPAT (c) binding in the brains of wild-type (WT)
(upper panels) and 5-HT2AR knockout (KO) mice (lower panels). In WT mice, note the expected high density for 5-HT2ARs as
visualized with [3H]mesulergine plus 10x7 M SB242084 in (A1) prefrontal cortex [cingulated (Cg1). Motor (M1, M2), AP:
2.10 mm] and, (A2) frontal cortex (FCx) and claustrum (CL) (AP: 0.74 mm). Parallel sections of the corresponding null mutant
mice (KO) show a conspicuous lack of binding (A3-A4). No diﬀerences between genotypes were noted for 5-HT2CRs as
visualized with [3H]mesulergine plus 10x7 M spiperone in the choroid plexus (ChP) (B1-B2) nor for 5-HT1ARs, as visualized with
[3H]8-OH-DPAT in prefrontal cortex (C1–C2) in WT and 5-HT2AR KO mice, respectively. Scale bar, 1 mm.
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baseline in WT mice (n=5) and 310¡68% of baseline
in 5-HT2AR KO mice (n=5) [time eﬀect : F(15, 120)=
10.85, p<0.0001].
However, clozapine (300 mM), olanzapine (100 mM)
and risperidone (100 mM) were unable to increase DA
output in the mPFC of 5-HT1AR KO mice (n=4–6)
(Fig. 4a–c). Two-way ANOVAs revealed signiﬁcant
diﬀerences in the eﬀects of APDs between the strains
of mice : (a) clozapine [genotype eﬀect : F(2, 19)=
7.83, p<0.01 ; time eﬀect : F(15, 285)=21.88, p<
0.0001 ; timergenotype interaction : F(30, 285)=3.79,
p<0.0001], (b) olanzapine [genotype eﬀect : F(2, 14)=
5.65, p<0.05 ; time eﬀect : F(15, 210)=7.42, p<0.0001;
timergenotype interaction : F(30, 210)=2.05, p<0.001]
and (c) risperidone [genotype eﬀect : F(2, 13)=8.66, p<
0.01 ; time eﬀect : F(15, 195)=10.41, p<0.0001; timer
genotype interaction : F(30, 195)=3.73, p<0.0001].
In addition, the local perfusion of clozapine
and olanzapine at increasing concentrations (30–
100–300 mM) signiﬁcantly raised DA concentration in
mPFC of both WT and 5-HT2AR KO, but not in
5-HT1AR KO mice in a concentration-dependent
Table 2. 5-HT1AR and 5-HT2CR labelling in diﬀerent brain regions from WT and 5-HT2AR KO mice
5-HT1AR [
3H]8-OHDPAT
(fmol/mg tissue)
5-HT2CR [
3H]Mesulergine+10x7 M spiperone
(fmol/mg tissue)
Prefrontal
cortex
Frontal
cortex
Frontal
cortex Claustrum
Choroid
plexus
WT 34.1¡0.5 23.1¡1.1 18.4¡3.2 18.0¡4.0 127.5¡4.2
5-HT2AR KO 32.5¡1.0 23.2¡1.7 13.6¡4.7 21.3¡4.6 128.6¡9.0
5-HT1AR labelling by [
3H]8-OHDPAT and 5-HT2CR labelling by [
3H]mesulergine+10x7 M spiperone were measured in diﬀerent
brain regions including prefrontal cortex (AP: 2.1 mm), frontal cortex and claustrum (AP:y0.74 mm) and lateral and medial
choroid plexuses (AP: aboutx1.58 mm). Results, expressed as fmol/mg tissue, are the means¡S.E.M. of 4–8 observations per
mouse (n=4) (one or two observations for each hemisphere of two consecutive sections per animal and four animals per group).
Non-signiﬁcant diﬀerences were observed between both genotypes (Student’s t test).
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Fig. 3. Local eﬀect of the 5-HT2A/2CR agonist DOI (100–300 mM) on the output of 5-HT (c) and DA (d) in the mPFC of wild-type
(WT) and 5-HT2AR knockout (KO) mice. The perfusion of DOI increased 5-HT and DA levels in mPFC of WT mice (n=10). Both
eﬀects were absent in 5-HT2AR KO mice (n=7–10). The administration of aCSF did not alter prefrontal 5-HT (a) and DA (b) in
either genotype (n=5–6). Data are expressed as mean¡S.E.M. See Results section for statistical analysis.
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manner (Fig. 5a, b). Two-way ANOVAs of AUC re-
vealed signiﬁcant diﬀerences in the eﬀects of APDs on
the diﬀerent genotypes : (a) clozapine [concentration
eﬀect : F(2, 40)=8.42, p<0.001; genotype eﬀect :
F(2, 40)=16.02, p<0.0001] and (b) olanzapine [con-
centration eﬀect : F(2, 31)=5.40, p<0.01 ; genotype
eﬀect : F(2, 31)=11.60, p<0.001]. Unlike DA, the con-
centration of 5-HT in mPFC dialysates was similarly
aﬀected by clozapine (300 mM) and olanzapine (100 mM)
in the three genotypes. A marginal reduction was
noted in WT and 5-HT2AR KO, but not in 5-HT1AR KO
mice (p=0.09 for clozapine ; p=0.17 for olanzapine;
one-way ANOVA of AUCs) (Fig. 5c).
Eﬀect of clozapine on mPFC DA output after
GPCR silencing with selective protection of 5-HT1A
or 5-HT2A/2C receptors in rats
To assess the involvement of 5-HT1A and 5-HT2A
receptors in the clozapine-induced increase of DA
output in rat PFC, we examined its eﬀect in control
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Fig. 4. The local administration of (a) clozapine (300 mM, n=9),
(b) olanzapine (100 mM, n=6–7) and (c) risperidone (100 mM,
n=5) increased similarly DA levels in mPFC of wild-type
(WT) and 5-HT2AR knockout (KO) mice. This eﬀect was not
observed when APDs were infused in the mPFC of 5-HT1AR
KO mice (n=4–6, a–c). Data are expressed as mean¡S.E.M.
See Results section for statistical analysis.
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Fig. 5. Local administration of (a) clozapine and (b)
olanzapine at increasing concentrations (30–100–300 mM)
raised a similar DA output in mPFC of wild-type (WT) and
5-HT2AR KO mice. This eﬀect was not observed when APDs
were perfused in the mPFC of 5-HT1AR KO mice. (c) Local
eﬀect of clozapine (300 mM) and olanzapine (100 mM) on 5-HT
output in mPFC of WT, 5-HT2AR KO and 5-HT1AR KO mice.
Data are AUCs (fractions 6–16) expressed as percentage of
baseline. n=4–9 mice for all groups, except for 300 mM
olanzapine in mPFC of 5-HT2AR KO mice, where n=3. See
Results section for statistical analysis. * p<0.05, ** p<0.01
vs. WT and 5-HT2AR KO mice.
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rats and in rats whose GPCRs were previously in-
activated by EEDQ together with a selective protection
of 5-HT1A or 5-HT2A/2C receptors in mPFC (Amargo´s-
Bosch et al. 2004, see Methods section).
Clozapine perfusion (300 mM) increased the DA out-
put in control rats (n=10) to 170¡14% of baseline but
to a much lower extent (a transient increase to 121¡
24% of baseline) in rats with preserved 5-HT2A/2CRs
(n=5) (Fig. 6a). Two-way ANOVAs revealed a signiﬁ-
cant group eﬀect [F(1, 13)=9.41, p<0.009], time eﬀect
[F(15, 195)=3.98, p<0.0001] and timergroup interac-
tion [F(15, 195)=3.23, p<0.0001].
We also tested the role of mPFC 5-HT1ARs in the
clozapine-induced DA release in rats using the EEDQ
model. 5-HT1ARs were unilaterally protected in rat
mPFC by local administration of WAY-100635
(300 mM) during EEDQ treatment (see Methods sec-
tion). In this group of rats, clozapine (300 mM) elicited
a signiﬁcant DA elevation (299¡57% of baseline, n=
6) which was greater than in control rats (170¡
14% of baseline, n=10 ; see above) (Fig. 6b). Two-way
ANOVAs revealed a signiﬁcant eﬀect of group
[F(1, 14)=8.17, p<0.01], time [F(15, 210)=14.08, p<
0.0001] and timergroup interaction [F(15, 210)=3.51,
p<0.0001].
Previous studies have shown that clozapine re-
versed the increase of cortical 5-HT release induced by
DOI (Bortolozzi et al. 2003). Since DOI also elevates DA
release in mPFC by a 5-HT2AR-dependent mechanism
(Bortolozzi et al. 2005), we examined whether cloza-
pine was able to counteract the increase in DA output
induced by DOI, despite its ability to increase DA
output by itself. DOI (300 mM)was locally administered
in the mPFC of control rats and of EEDQ-treated rats
with protected 5-HT2A/2CRs (n=6 and 8, respectively).
DOI increased DA output in control rats and in those
treated with EEDQ (with protected 5-HT2A/2CRs).
Two-way ANOVAs revealed a signiﬁcant eﬀect of
time [time eﬀect : F(9, 108)=18.88, p<0.0001 ; non-
signiﬁcant eﬀects of the group or timergroup inter-
actions ; fractions 1–10) (Fig. 7a). The co-perfusion of
clozapine (300 mM) reversed the eﬀect of DOI on
DA output in the mPFC of control rats but not of
those treated with EEDQ with protected 5-HT2A/2CRs
[group eﬀect : F(1, 12)=11.58, p<0.005; time eﬀect :
F(15, 180)=8.87, p<0.0001; timergroup interaction :
F(15, 180)=3.69, p<0.0001; fractions 1–16] suggesting
that this eﬀect does not involve blockade of 5-HT2ARs.
To examine the involvement of 5-HT1ARs in the
clozapine-mediated reversal of DOI action on PFC DA
output, we conducted additional experiments in
which we evaluated the ability of the 5-HT1A agonist
BAY x 3702 to antagonize the DOI-mediated DA in-
crease. The local perfusion of 30 mM BAY x 3702 re-
versed the DA elevation in PFC induced by local DOI
administration [group eﬀect : F(1, 7)=31.60, p<0.0008;
time eﬀect : F(15, 105)=7.26, p<0.0001; timergroup
interactions : F(15, 105)=3.04, p<0.0001] (Fig. 7b).
Autoradiographic examination of 5-HT1A and
5-HT2A/2C receptors in the GPCR-silencing model
We performed additional autoradiographic exper-
iments in rats not subjected to drug infusion (except
for WAY-100635 or ritanserin administration during
EEDQ treatment) to determine the site and extent
of 5-HT1AR and 5-HT2A/2CR protection in the
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Fig. 6. (a) The perfusion of 300 mM clozapine in mPFC of
control rats increased local DA output (n=10). This eﬀect
was absent in the mPFC of rats whose GPCRs were silenced
by a prior EEDQ injection (6 mg/kg i.p.) and their prefrontal
5-HT2A/2CRs had been protected by ritanserin (300 mM)
administration through the microdialysis probe (n=5)
(see Methods section). (b) Conversely, clozapine
administration (300 mM) elicited a signiﬁcant DA elevation
in mPFC of rats treated with EEDQ whose 5-HT1ARs were
preserved by prior WAY-100635 (300 mM) administration
(n=6). This eﬀect was signiﬁcantly greater than in control
rats (n=10). Data are expressed as mean¡S.E.M. See Results
section for statistical analysis.
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EEDQ-treated rats. EEDQ evoked a massive reduction
of 5-HT1AR and 5-HT2A/2CR density (Figs. 8 and 9).
Local, unilateral ritanserin perfusion by reverse
dialysis in the mPFC partially avoided 5-HT2A/2CR
inactivation by EEDQ. Densities of 5-HT2A/2CR-
binding sites in the ipsilateral (protected) mPFC at
AP coordinates (in mm) 3.20–3.70 ranged from 61%
to 83% (mean 71¡4%, n=4 rats) relative to mPFC
of control rats in the same hemisphere (n=2). In the
contralateral (unprotected) side, 5-HT2A/2CR-binding
sites were 31¡2% (n=4 rats) relative to the mPFC in
the same hemisphere of control rats (n=2). One-way
ANOVA indicated that [3H]mesulergine binding in
ipsilateral mPFC of the GPCR-silenced+5-HT2A/2CR-
protected group was signiﬁcantly diﬀerent from con-
tralateral mPFC (p<0.001) (Fig. 8a, b). Coronal sections
from an AP coordinate distant from local ritanserin
administration (e.g. 4.20 mm), revealed a marginally
signiﬁcant diﬀerence between ipsilateral and con-
tralateral sides (68¡3 vs. 43¡3% relative to PFC in the
same hemispheres of control rats, respectively,
p=0.058).
Figure 9a shows autoradiograms of 5-HT1ARs
in PFC at AP 3.20–3.70 mm from diﬀerent groups
of rats : control (n=2), GPCR-silenced (n=2), GPCR-
silenced+5-HT2A/2CR-protected (n=4) and GPCR-
silenced+5-HT1AR-protected (n=4). WAY-100635
perfusion partially protected 5-HT1ARs from inacti-
vation by EEDQ. One-way ANOVA indicated that
[3H]8-OH-DPAT binding in ipsilateral PFC of the
GPCR-silenced+5-HT1AR-protected group was sig-
niﬁcantly diﬀerent from contralateral PFC (51¡7 vs.
17¡4% relative to ipsilateral and contralateral cortices
of control rats, respectively, p<0.001) (Fig. 9b). In this
case, 5-HT1AR density was also signiﬁcantly diﬀerent
between both ipsilateral and contralateral mPFC at AP
y4.20 mm of GPCR-silenced+5-HT1AR-protected rats
(data not shown).
Discussion
The main ﬁnding of the present study is that APDs
such as clozapine, olanzapine and risperidone do not
require interaction with 5-HT2ARs to elevate DA
release in rodent mPFC. This observation is relevant to
understanding the neurobiological basis of the su-
perior therapeutic action of these APDs in schizo-
phrenia (Leucht et al. 2009) and may help to develop
new drugs overcoming the limitations of existing
treatments.
Methodological considerations
Two experimental models have been used in the
present study: (a) mice lacking 5-HT1A or 5-HT2A re-
ceptors, and (b) rats, whose GPCRs were inactivated
by EEDQ using selective protection of 5-HT1A or
5-HT2A/2C receptors.
The lack of 5-HT1ARs in KO mice (Parks et al. 1998)
was assessed by receptor autoradiography, electro-
physiology and microdialysis (Amargo´s-Bosch et al.
2004; present study). Here we extend these obser-
vations to 5-HT2AR KO mice (Fiorica-Howells et al.
2002). A preliminary account of these data has been
presented previously (Bortolozzi et al. 2007a).We show
the absence of compensatory changes of 5-HT1AR and
5-HT2CR proteins in mice lacking 5-HT2ARs, similarly
to Popa et al. (2005)who reported an unaltered 5-HT2CR
mRNA expression in 5-HT2AR KO mice. Consistent
with the autoradiographic data, the preferential
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Fig. 7. (a) The perfusion of 300 mM DOI (5-HT2A/2C agonist)
increased DA output in the mPFC of control rats and of rats
treated with EEDQ and whose mPFC 5-HT2A/2CRs were
unilaterally preserved by prior ritanserin administration. The
perfusion of clozapine (300 mM) reversed the eﬀect of DOI
only in control rats (n=6–8) but not in those with protected
5-HT2A/2CR. (b) In control rats, the local perfusion of
BAY x 3702 (30 mM) antagonized the increase of DA output in
mPFC induced by the local administration of DOI (300 mM)
(n=5). Data are expressed as mean¡S.E.M. See Results section
for statistical analysis.
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5-HT2AR agonist DOI did not increase 5-HT and DA
release in the mPFC of 5-HT2AR KO mice, an eﬀect
requiring the activation of post-synaptic 5-HT2ARs
on pyramidal cells projecting to the midbrain mono-
aminergic nuclei (Bortolozzi et al. 2005; Martı´n-Ruiz
et al. 2001; Va´zquez-Borsetti et al. 2009).
To examine the role of 5-HT1A and 5-HT2A/2C re-
ceptors in rat PFC, we used a previously described
model (Amargo´s-Bosch et al. 2004), consisting in the
selective protection of one or other receptor from
the inactivating action of EEDQ (Battaglia et al. 1987;
Gozlan et al. 1994; Keck & Lakoski, 2000) through
the local administration of antagonists (WAY-100635
or ritanserin, respectively) to occupy 5-HT1A or
5-HT2A/2C receptors in mPFC during EEDQ treatment.
This model is far from the speciﬁcity of KO mice yet it
allows for a preliminary examination of the involve-
ment of 5-HT1A and 5-HT2A receptors on the eﬀects of
APDs in the rat brain.
The present autoradiographic data indicate that
(1) EEDQ produces a massive loss of 5-HT1A and
5-HT2A/2C receptors in vivo, and (2) the local protection
of 5-HT1A or 5-HT2A/2C receptors by the respective
antagonists was relatively successful, as shown by dif-
ferences in receptor density between (a) ipsilateral
(protected) and contralateral (unprotected) mPFCs,
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Fig. 8. (a) Representative autoradiograms showing the density of 5-HT2A/2CRs labelled with [
3H]mesulergine in coronal sections
of PFC (AP in mm: 3.70–3.20) from diﬀerent pretreatment groups : (A1) controls (rats received the EEDQ vehicle i.p. and aCSF
through the dialysis probe), (A2) GPCR-silenced rats (injected with 6 mg/kg i.p EEDQ and perfused with aCSF through the
dialysis probe), (A3) GPCR-silenced+5-HT1AR-protected rats (treated with 6 mg/kg i.p. EEDQ while 300 mM WAY-100635 was
perfused through the dialysis probe), and (A4) GPCR-silenced+5-HT2A/2CR-protected rats (treated with 6 mg/kg i.p. EEDQ
while 300 mM ritanserin was perfused through the dialysis probe). A5 shows non-speciﬁc binding. Panels A1a–A4a are
photomicrographs showing enlargements of the marked area in panels A1–A4. Note the higher 5-HT2A/2CR binding in ipsilateral
(protected) mPFCwith respect to the contralateral (unprotected) side of panel A4 and the very low occupancy for 5-HT2A/2CRs in
both hemispheres of panels A2 and A3. Scale bars, 2 mm (A1–A4) and 500 mm (A1a–A4a). (b) Densitometric quantiﬁcation of
5-HT2A/2CR binding in mPFC including cingulate, prelimbic and infralimbic cortices of the diﬀerent group of rats (B1–B4). Bars
represent mean 5-HT2A/2CR fmol/mg tissue¡S.E.M. of 4–8 observations (two or four observations at left and right hemispheres
of two consecutive sections per animal and two to four animals per group). ** p<0.001 signiﬁcantly diﬀerent from corresponding
contralateral (C) and ipsilateral (I) mPFC of control rats, ++ p<0.001 signiﬁcantly diﬀerent from contralateral mPFC of
GPCR-silenced+5-HT2A/2CR-protected rats, using one-way ANOVA followed by Newman–Keuls post-hoc test.
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and (b) the ipsilateral side in EEDQ-treated and control
rats. The fact that receptor densities in protected
sides were lower than in control rats may be partly due
to the damage caused by the dialysis probe, which
forced us to use coronal sections relatively distant from
the administration site, and thus,with lower antagonist
occupancy than sites close to the microdialysis probes
receiving a higher antagonist concentration.
5-HT1ARs have a great sensitivity to EEDQ in vitro
(Gozlan et al. 1994). The present in-vivo data are con-
sistent with this view, since EEDQ reduced 5-HT1A
and 5-HT2A/2C receptor densities to 15% and 30% of
controls, respectively. Similar diﬀerences have been
noted for DA D1 and D2 receptors (see Cox &
Waszczak, 1993 ; Hemsley & Crocker, 2001 and refer-
ences therein). Interestingly, despite measured recep-
tor densities in protected sides being lower than 100%
of controls, DOI increased DA release to the same ex-
tent in the mPFC of control rats and of those receiving
EEDQ+ritanserin, indicating that local 5-HT2A/2CRs
remained entirely functional using this experimental
paradigm. Similar results have been reported for
5-HT1AR agonists (Amargo´s-Bosch et al. 2004).
Role of 5-HT1A and 5-HT2A receptors in the
APD-induced DA release
Despite the diverse pharmacological proﬁles of
APDs (Arnt & Skarsfeldt, 1998), they share the ability
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Fig. 9. (a) Representative autoradiograms showing the density of 5-HT1ARs labelled with [
3H]8-OH-DPAT in coronal sections of
PFC (AP in mm: 3.70–3.20) from diﬀerent pretreatment groups : (A1) controls (rats received the EEDQ vehicle i.p. and aCSF
through the dialysis probe), (A2) GPCR-silenced rats (injected with 6 mg/kg i.p. EEDQ and perfused with aCSF through the
dialysis probe), (A3) GPCR-silenced+5-HT2A/2CR-protected rats (injected with 6 mg/kg i.p. EEDQ while 300 mM ritanserin was
perfused through the dialysis probe), and (A4) GPCR-silenced+5-HT1AR-protected rats (injected with 6 mg/kg i.p. EEDQwhile
300 mM WAY-100635 was perfused through the dialysis probe). A5 shows non-speciﬁc binding. Panels A1a–A4a are
photomicrographs showing enlargements of the marked area in panels A1–A4. Note the higher 5-HT1AR binding in ipsilateral
(protected) mPFC with respect to the contralateral (unprotected) side of A4 and the very low occupancy for 5-HT1ARs in both
hemispheres of panels A2 and A3. Scale bars, 2 mm (A1–A4) and 500 mm (A1a–A4a). (b) Densitometric quantiﬁcation of 5-HT1AR
binding in mPFC including cingulate, prelimbic and infralimbic cortices of the diﬀerent group of rats (B1–B4). Bars represent
mean 5-HT1AR fmol/mg tissue¡S.E.M. of 4–8 observations (two or four observations at left and right hemispheres of two
consecutive sections per animal and two to four animals per group). ** p<0.001 signiﬁcantly diﬀerent from corresponding
contralateral (C) and ipsilateral (I) mPFC of control rats, ++ p<0.001 signiﬁcantly diﬀerent from contralateral mPFC of
GPCR-silenced+5-HT1AR-protected rats, using one-way ANOVA followed by Newman–Keuls post-hoc test.
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to increase DA release in rodent mPFC through 5-
HT1AR activation (Bortolozzi et al. 2007b ; Dı´az-Mataix
et al. 2005; Ichikawa et al. 2001; Li et al. 2009; Rollema
et al. 1997, 2000). This eﬀect was attributed to simul-
taneous blockade of 5-HT2A and D2 receptors
(Ichikawa et al. 2001) yet it seems to depend exclus-
ively on the activation of 5-HT1ARs in mPFC
(Bortolozzi et al. 2007b ; Dı´az-Mataix et al. 2005). In
the present study, we further conﬁrm these previous
observations in 5-HT1AR KO mice and show that 5-
HT2AR blockade is not a requirement. Further, we ex-
tend these observations to rat mPFC, where clozapine
increased local DA release in presence of y50% of
mPFC 5-HT1ARs but not in rats whose 5-HT1ARs were
inactivated to 15% of controls by EEDQ treatment. The
greater DA increase induced by clozapine in rats
whose GPCRs were silenced by EEDQ – yet with pre-
served 5-HT1ARs – suggests an additional regulatory
role of other receptors in the clozapine-evoked DA
release (e.g. DA D2, a2-adrenoceptors) once the DA
increase has been induced by 5-HT1AR stimulation. It
has been suggested that WAY-100635 may also bind to
DA D4 receptors in addition to 5-HT1ARs (Chemel et al.
2006; Martel et al. 2007) and therefore, some protection
for D4 receptors may exist in the EEDQ+WAY-100635
model. Thus, it cannot be excluded that D4 receptors
play a role in the clozapine-induced cortical DA re-
lease using this model in rat mPFC despite its eﬀects
being totally absent in 5-HT1AR KOmice (Dı´az-Mataix
et al. 2005; present study).
The apparent bell-shaped dose–eﬀect relationship
of olanzapine on DA release (Fig. 5b) suggests the
involvement of other prefrontal monoaminergic re-
ceptors (e.g. a1-adrenoceptors ; Amargo´s-Bosch et al.
2003) for which olanzapine shows nM aﬃnity (Arnt &
Skarsfeldt, 1998).
The similar in-vivo DA increases in PFC produced
by several APDs (Dı´az-Mataix et al. 2005; Ichikawa
et al. 2001), does not bear a relationship with their in-
vitro aﬃnities for 5-HT1ARs, e.g. high for ziprasidone,
low for clozapine and risperidone (yet clozapine oc-
cupies 5-HT1ARs in vivo ; Chou et al. 2003) or negligible
for olanzapine (Arnt & Skarsfeldt, 1998; Bymaster et al.
1996; Newman-Tancredi et al. 1998). The exact way by
which APDs lacking in-vitro aﬃnity interact in vivo
with 5-HT1AR-mediated neurotransmission is unclear.
The DA output induced by APDs and 5-HT1A agonists
was cancelled by co-perfusion with the GABAA an-
tagonist bicuculline, suggesting the involvement of
5-HT1ARs in GABA interneurons (Dı´az-Mataix et al.
2005). Given the inhibitory nature of 5-HT1ARs, a
preferential action of APDs on 5-HT1ARs located
on GABA interneurons would eventually result in an
increased excitatory cortical output to the VTA to en-
hance DA neuron activity (Gessa et al. 2000), an eﬀect
qualitatively similar to that of selective 5-HT1A ag-
onists (Dı´az-Mataix et al. 2005, 2006).
The increase in mPFC DA release produced by
APDs might theoretically result from an interaction
between 5-HT1A and 5-HT2A receptors in neurons co-
expressing these receptors (Amargo´s-Bosch et al. 2004).
Thus, 5-HT2AR blockade by APDs might alter the
physiological balance between 5-HT1A and 5-HT2A re-
ceptors, resulting in an increase of 5-HT1AR-mediated
neurotransmission. However, the present data do not
support this possibility, since the APDs clozapine,
olanzapine and risperidone increased a similar DA re-
lease in the mPFC of mice lacking 5-HT2ARs (with no
alteration of 5-HT1AR density) and in WT controls.
These results in mice were conﬁrmed by rat data
showing that clozapine was ineﬀective in enhancing
DA output in the mPFC of rats whose 5-HT1ARs
were inactivated (y15% of controls), yet whose
5-HT2A/2CRs were protected (y70% of controls).
Interestingly, and despite its ability to stimulate DA
release when given alone, clozapine counteracted the
increase in PFC DA output induced by DOI, suggest-
ing a diﬀerent eﬀect in PFC in basal or stimulated
conditions. This pattern is similar to that observed
in some electrophysiological studies, where clozapine
displays a state-dependent action, reducing neuronal
hyperactivity (e.g. Homayoun & Moghaddam, 2007;
Kargieman et al. 2007; Schwieler & Erhardt, 2003).
Thus, clozapine would activate the mesocortical DA
system from basal conditions but would dampen cor-
tical hyperactivity.
Clozapine could not reverse the eﬀect of DOI
in GPCR-silenced+5-HT2A/2CR-protected rats. In this
group, 5-HT2ARs were entirely functional, as indicated
by the local eﬀect of DOI on DA output, comparable
to that in controls. The inability of clozapine to
counteract DOI’s eﬀect in these rats suggests the in-
volvement of other receptors, diﬀerent from 5-HT2ARs,
to reverse the action of DOI in control rats. Although
we could not perform a systematic study, the com-
parable eﬀect of clozapine and the selective 5-HT1AR
agonist BAY x 3702 suggests the involvement of
5-HT1ARs.
Overall, these ﬁndings indicate that the stimulation
of mesocortical DA release by APDs does not require
the presence of 5-HT2ARs and suggest that these drugs
activate 5-HT1ARs to enhance cortical DA neuro-
transmission. Alternatively, it is conceivable that other
receptor–receptor interactions might explain this
marked discrepancy between in-vitro and in-vivo ac-
tions of APDs at 5-HT1ARs.
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Functional consequences
The present data, obtained in mice and rats using two
diﬀerent experimental models (permanent 5-HT re-
ceptor KO mice and GPCR inactivation with selective
protection of 5-HT receptors) indicate that blockade of
5-HT2ARs by APDs is not a necessary step to elevate
DA release and that this eﬀect is mediated by indirect
activation of 5-HT1ARs in PFC. The molecular/cellular
basis of the present in-vivo results is not known.
These observations do not preclude at all that 5-
HT2AR blockade by APDs participates in their thera-
peutic action. Our conclusions are restricted to the role
of 5-HT receptors required to enhance mesocortical
DA, an eﬀect potentially important for the actions
of APDs on negative symptoms and cognitive deﬁcits
of schizophrenia patients. Given the lack of adequate
treatment of these problems, further detailed studies
are required to examine the ability of APDs – and
in particular, of clozapine – to stimulate cortical 5-
HT1AR-mediated neurotransmission despite their low
or negligible in-vitro aﬃnity.
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